{
    "info": {
        "nct_id": "NCT05130866",
        "official_title": "A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas",
        "inclusion_criteria": "1. ≥12 years of age and weighing at least 40 kg\n2. Progressive meningioma that is amenable to volumetric analysis\n3. Has either 1) sporadic meningioma with confirmed NF2 mutation; or, 2) confirmed diagnosis of NF2 disease (revised Manchester criteria); or, 3) at least one NF2-related tumor (with pathogenic germline or proven mosaic NF2 variant)\n4. Adequate bone marrow function\n5. Has provided written informed consent/assent to participate in the study\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "1. Progressive disease associated with significant or disabling clinical symptoms likely to require surgery or radiation therapy within the next 3 months.\n2. Received prior surgery, radiosurgery, or laser interstitial thermal therapy in the target tumor, or immediately adjacent to the target tumor within 6 months prior to screening.\n3. Received an anti- tumor agent for meningioma within 3 months, or 5 half-lives (whichever is longer), prior to screening.\n4. History of an active malignancy within the previous 3 years except for localized cancers that are considered cured, and, in the opinion of the investigator, present a low risk of recurrence.\n5. Received another investigational drug within 30 days prior to screening\n6. Pregnant, lactating, or is planning to attempt to become pregnant or impregnate someone during this study or within 90 days after the last dose of IMP.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Progressive meningioma that is amenable to volumetric analysis",
            "criterions": [
                {
                    "exact_snippets": "Progressive meningioma",
                    "criterion": "meningioma",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "amenable to volumetric analysis",
                    "criterion": "meningioma",
                    "requirements": [
                        {
                            "requirement_type": "amenable to volumetric analysis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Has provided written informed consent/assent to participate in the study",
            "criterions": [
                {
                    "exact_snippets": "Has provided written informed consent/assent to participate in the study",
                    "criterion": "written informed consent/assent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Has either 1) sporadic meningioma with confirmed NF2 mutation; or, 2) confirmed diagnosis of NF2 disease (revised Manchester criteria); or, 3) at least one NF2-related tumor (with pathogenic germline or proven mosaic NF2 variant)",
            "criterions": [
                {
                    "exact_snippets": "sporadic meningioma with confirmed NF2 mutation",
                    "criterion": "sporadic meningioma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NF2 mutation status",
                            "expected_value": "confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed diagnosis of NF2 disease (revised Manchester criteria)",
                    "criterion": "NF2 disease diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "confirmed"
                        },
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "revised Manchester criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one NF2-related tumor (with pathogenic germline or proven mosaic NF2 variant)",
                    "criterion": "NF2-related tumor",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "tumor"
                            }
                        },
                        {
                            "requirement_type": "NF2 variant type",
                            "expected_value": [
                                "pathogenic germline",
                                "proven mosaic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. ≥12 years of age and weighing at least 40 kg",
            "criterions": [
                {
                    "exact_snippets": "≥12 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "weighing at least 40 kg",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "minimum weight",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Adequate bone marrow function",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "6. Pregnant, lactating, or is planning to attempt to become pregnant or impregnate someone during this study or within 90 days after the last dose of IMP.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "is planning to attempt to become pregnant ... during this study or within 90 days after the last dose of IMP",
                    "criterion": "intention to become pregnant",
                    "requirements": [
                        {
                            "requirement_type": "intention during study or within 90 days after last dose of IMP",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "is planning to attempt to ... impregnate someone during this study or within 90 days after the last dose of IMP",
                    "criterion": "intention to impregnate someone",
                    "requirements": [
                        {
                            "requirement_type": "intention during study or within 90 days after last dose of IMP",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Received an anti- tumor agent for meningioma within 3 months, or 5 half-lives (whichever is longer), prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "Received an anti- tumor agent for meningioma within 3 months, or 5 half-lives (whichever is longer), prior to screening.",
                    "criterion": "anti-tumor agent for meningioma",
                    "requirements": [
                        {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of an active malignancy within the previous 3 years except for localized cancers that are considered cured, and, in the opinion of the investigator, present a low risk of recurrence.",
            "criterions": [
                {
                    "exact_snippets": "History of an active malignancy within the previous 3 years",
                    "criterion": "active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_years",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "except for localized cancers that are considered cured, and, in the opinion of the investigator, present a low risk of recurrence",
                    "criterion": "localized cancers",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "cured"
                        },
                        {
                            "requirement_type": "risk_of_recurrence",
                            "expected_value": "low"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Received another investigational drug within 30 days prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Received another investigational drug within 30 days prior to screening",
                    "criterion": "receipt of another investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing reference",
                            "expected_value": "prior to screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Progressive disease associated with significant or disabling clinical symptoms likely to require surgery or radiation therapy within the next 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Progressive disease",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "progressive"
                        }
                    ]
                },
                {
                    "exact_snippets": "significant or disabling clinical symptoms",
                    "criterion": "clinical symptoms",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "significant",
                                "disabling"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "likely to require surgery or radiation therapy within the next 3 months",
                    "criterion": "need for surgery or radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "likelihood",
                            "expected_value": "likely"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Received prior surgery, radiosurgery, or laser interstitial thermal therapy in the target tumor, or immediately adjacent to the target tumor within 6 months prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "Received prior surgery, radiosurgery, or laser interstitial thermal therapy in the target tumor",
                    "criterion": "prior local therapy to target tumor",
                    "requirements": [
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "surgery",
                                "radiosurgery",
                                "laser interstitial thermal therapy"
                            ]
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "in the target tumor"
                        }
                    ]
                },
                {
                    "exact_snippets": "Received prior surgery, radiosurgery, or laser interstitial thermal therapy ... immediately adjacent to the target tumor within 6 months prior to screening",
                    "criterion": "prior local therapy adjacent to target tumor",
                    "requirements": [
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "surgery",
                                "radiosurgery",
                                "laser interstitial thermal therapy"
                            ]
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "immediately adjacent to the target tumor"
                        },
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}